New Delhi: Hester Biosciences has signed an agreement towards receiving indigenously developed technology from Indian Council of Agricultural Research – National Institute of High Security Animal Diseases (ICAR-NIHSAD), for the development and commercialization of the Low Pathogenic Avian Influenza (H9N2 strain) Inactivated Vaccine for poultry.
The agreement was signed on 27 December 2022 at the office of Agrinnovate India, New Delhi. Agrinnovate is a government entity that acts as an interface between ICAR and the stakeholders in the agriculture sector, which includes technology transfers for vaccine manufacturing in the veterinary sector.
The meeting was attended by the Director General (DG) of ICAR, Dr. Himanshu Pathak; Deputy DG of ICAR, Dr. B N Tripathi; Assistant DG of ICAR, Dr. Ashok Kumar. It also witnessed the presence of Dr. Praveen Malik, CEO, Agrinnovate India; Dr. Aniket Sanyal, Director, NIHSAD; Rajiv Gandhi, CEO & MD, Hester Biosceinces; and Dr. Manoj Kumar, CSO, Hester Biosciences.
Low Pathogenic Avian Influenza H9N2 Strain causes comorbidity in poultry flocks throughout the year, leading to huge economic losses to the poultry farmers. The disease generally has low mortality rate up to 6% but can increase significantly in the presence of other infections. It could also lead to an irreversible egg production drop (up to 50%) in layer birds and a performance loss in broilers.
This indigenously developed inactivated H9N2 vaccine for poultry is developed using a local isolate, thereby ensuring that the vaccine is made from the local strain and not by importing any exotic strain.
This development achieves the country’s objective towards making India Aatmanirbhar (self-reliant).
As per Agrinovate:
-
The vaccine has passed the sterility, safety, and efficacy testing in experimental trials under laboratory conditions.
-
The vaccine provides protective immunity in chickens for approximately 6 months.
